



## Table of Contents

- 1 Editorial on the Proper Use of Modifier 63 for Congenital Cardiac Catheterization – Educating User and Payer Alike  
*Sergio Bartakian, MD, FAAP, FACC, FSCAI*
- 6 The PICS Society Advocacy Program: Power in Numbers! Part 1  
*Kamel Shibbani, MD;  
Natalie Poli, Ed.S;  
Norm Linsky, MPA, MA*
- 8 Delayed Aortic Coarctation Balloon Dilatation After Duct Coil Occlusion  
*Francisco Javier Ozores Suárez, MD, MS;  
Francisco Diaz Ramirez, MD;  
Juan Carlos Ramiro Novoa, MD;  
Alejandro González Veliz, MD*
- 11 Meeting Calendar
- 12 Medical News
  - Nationwide Children's Hospital Once Again Named on U.S. News & World Report's 2021-22 Best Children's Hospitals Honor Roll
  - Phoenix Children's Ranked in all 10 Specialties By U.S. News & World Report's "Best Children's Hospitals"

# Editorial on the Proper Use of Modifier 63 for Congenital Cardiac Catheterization – Educating User and Payer Alike

*Sergio Bartakian, MD, FAAP, FACC, FSCAI*

In 2016, members from the Society of Cardiovascular Angiography and Interventions (SCAI), recognizing the lack of codes in the existing CPT® coding structure to capture the work for congenital cardiac catheterization procedures, formed the Congenital Interventional Cardiology Coding Workgroup (CICCW). Since that time, the CICCW has been very successful creating numerous new CPT® codes (Table 1) and correcting several long-standing errors in the existing CPT® guidelines, as well.

TABLE 1

Project	CPT Meeting Presented	RUC Survey	RUC Meeting Presented	Status	When Available	New code (wRVU value)
Pulmonary artery angiography with device closure bundles	June 2017	n/a	n/a	Passed	Dec 2017	n/a
new pericardiocentesis codes	Sep 2018	Nov 2018	Dec 2018	Passed	1-Jan-2020	33016 (4.4), 33017 (4.62), 33018 (5.4)
Modifier 63 for infants under 4 kg	Sep 2018	n/a	n/a	Passed	Jun 2019	n/a
Atrial septostomy	Feb 2020	Feb 2020	Apr 2020	Passed	1-Jan-2021	33741 (14.0)
Intracardiac stenting	Feb 2020	Feb 2020	Apr 2020	Passed	1-Jan-2021	33745 (20.0) and 33746 (8.0)
ICE for use with broader range of cardiac cath procedures	May 2020	n/a	n/a	Passed	1-Jan-2022	n/a (existing code)
Congenital diagnostic catheterization base codes	May 2020	Jun 2020	Oct 2020	Passed	1-Jan-2022	93X1X - 93X5X
New Thermodilation code for congenital diagnostic catheterization	May 2020	Jun 2020	Oct 2020	Passed	1-Jan-2022	93X6X
Stent / angioplasty for repair of coarctation of the aorta	Oct 2020	Oct 2020	Jan 2021	Passed	1-Jan-2022	338X0, 338X1, 338X2
Pulmonary artery / ductal stenting	Feb 2021	Feb 2021	Oct 2021	Passed CPT	1-Jan-2023	
Pulmonary Angiography	Feb 2021	May 2021	Oct 2021	Passed CPT	1-Jan-2023	
Completed	In process / scheduled					

Among the many improvements, a correction was made to add the extensive list of congenital cardiac catheterization codes to the 90000 Code Series of the Medicine / Cardiovascular Section, to be included for use with modifier 63. Despite this change, the specialty continues to meet significant resistance from the payer community with regards to inappropriate denials. The denials stem from incorrect internal guidance on the part of most health insurance companies.

Some payers have incorrectly instructed their staff that the 63 modifier is not to be used to report procedures performed to treat congenital defects. This is entirely false as the modifier is precisely intended for this reason. The entire list of the 90000 congenital cardiac catheterization codes is for exactly that purpose, congenital cardiac defects. The AMA CPT® guidelines do not instruct any limitation for the use of modifier 63 due to the presence of a congenital defect. In fact, the only limitation is for the infant to be under 4 kg body weight at time of procedure.

# AUGUST 2021

International Edition

Vol. 19 - Issue 8

## TABLE OF CONTENTS

- 1 **Editorial on the Proper Use of Modifier 63 for Congenital Cardiac Catheterization – Educating User and Payer Alike**  
*Sergio Bartakian, MD, FAAP, FACC, FSCAI*
- 6 **The PICS Society Advocacy Program: Power in Numbers! Part 1**  
*Kamel Shibbani, MD; Natalie Poli, Ed.S; Norm Linsky, MPA, MA*
- 8 **Delayed Aortic Coarctation Balloon Dilatation After Duct Coil Occlusion**  
*Francisco Javier Ozores Suárez, MD, MS; Francisco Diaz Ramirez, MD; Juan Carlos Ramiro Novoa, MD; Alejandro González Veliz, MD*
- 11 **Meeting Calendar**
- 12 **Medical News**
  - Nationwide Children's Hospital Once Again Named on U.S. News & World Report's 2021-22 Best Children's Hospitals Honor Roll
  - Phoenix Children's Ranked in all 10 Specialties By U.S. News & World Report's "Best Children's Hospitals"



## Publish

- Written by doctors and their team
- Case studies, articles, research findings
- Submit on your schedule
- Print and electronic
- Published within 3 months of submission
- No fees

## Recruit

- In print and electronic monthly issue
- On our website
- In our monthly Email Blast
- No cost for CCT to create the ad
- Multiple sizes available



CONGENITAL  
CARDIOLOGY  
TODAY



Subscribe Electronically  
Free on Home Page  
[www.CongenitalCardiologyToday.com](http://www.CongenitalCardiologyToday.com)



Other payers provide incorrect guidance to deny claims which include the term “infant or neonate” in the procedure code. This is also a grossly misstated fallacy. Although all patients under 4 kg are infants and/or neonates, not all infants and/or neonates weigh less than 4 kg.

The official definition of the term infant is for any child under one year of age; and clearly, the far majority of children under one year of age will not be less than 4 kg. CPT® guidance is very clear about which codes specifically include this increased complexity as “the typical patient” for the given CPT® code. These are found in Appendix F and are the only procedures which inherently include the additional complexity for which modifier 63 is intended.

Finally, here is a sample from one payer which states a necessity to have additional documentation, not unlike guidance for modifier 22.

“Documentation from the patient's record must indicate the significantly greater effort required and the reason for the additional work which may include, but not be limited to, increased intensity or time, technical difficulty of procedure that is not described by a more comprehensive procedure code, severity of the patient's condition, or increased physical and mental effort.” In fact, there is no other requirement for properly appending modifier 63, aside from the patient weight at time of procedure being under 4 kg, and the specific code be in the approved sections of CPT®. It goes without saying, but modifier 63 is not modifier 22. The documentation regarding the reason for increased intensity, greater effort, technical skill, etc. lies solely on the fact that the child is less than 4 kg. Nothing else is needed to justify this work. To further suggest that “a more comprehensive procedure code” could be used is simply demonstrating the total lack of understanding of coding for congenital cardiac catheterization that is so widespread in the healthcare industry.

The members at SCAI and ACC have spent a great deal of time and effort in creating a comprehensive coding framework to capture the extremely complex nature of coding for this specialty. A great deal of collaboration has taken place with CPT® staff, advisors, and panel members to devise a structure which captures the work performed accurately. It is irresponsible for payers to disregard this effort by creating additional internal guidance which results in inappropriate denials for this very complex work.

For any questions regarding the proper use of CPT® codes for congenital cardiac catheterization, it is strongly advised to reach out to SCAI and/or ACC staff for clarification and guidance. Deb Mariani, SCAI staff, [dmariani@scai.org](mailto:dmariani@scai.org) or James Vavricek, ACC staff, [jvavricek@ACC.org](mailto:jvavricek@ACC.org).

Dr. Bartakian is a board-certified pediatrician and pediatric cardiologist who practices full time in the specialty of congenital cardiac catheterization. He is a former CPT® Alternate Advisor for SCAI and a current AMA RUC Panel member.




**SERGIO BARTAKIAN, MD, FAAP, FACC, FSCAI**  
Adult AMA CPT® Advisor for SCAI  
Congenital Interventional Cardiologist  
Children's Hospital of Michigan  
Detroit, MI, USA  
[dctrbar@gmail.com](mailto:dctrbar@gmail.com)

## Hospital Directory 2021-2022 Coming Mid-August

- Currently updating listings
- Hospitals that offer Open Heart Surgery for Children in North America
- Contact information at each hospital for Chief of Pediatric Cardiology & Fellowship Director
- Lists each hospital's Pediatric Cardiologists & Cardiothoracic Surgeons
- Distributed to Division Chiefs by mail
- Hard copies will be available at CCT's booth at PICS 2021
- Electronic version available on CCT's website:  
[www.congenitalcardiologytoday.com](http://www.congenitalcardiologytoday.com)

# RIGHT CHOICE.



**Melody™**  
Transcatheter Pulmonary  
Valve (TPV) System



Not intended to constitute medical advice or in any way replace the independent medical judgment of a trained and licensed physician with respect to any patient needs or circumstances. Melody TPV is not suitable for all patients and ease of use, outcomes, and performance may vary. See the Instructions for Use for indications, contraindications, precautions, warnings, and adverse events.

Restoring lives for  
**13**  
years and counting.

The only transcatheter pulmonary valve specifically designed for RVOT conduits and bioprosthetic valves. The longest studied transcatheter valve, with the largest body of clinical evidence at over 10 years.\* More than 16,000 patients' lives have been changed over 13 years, and counting.

**Melody TPV — The Right Choice  
for Your Patients**

\*Melody Transcatheter Pulmonary Valve Study:  
Post Approval Study of the Original IDE Cohort.  
©2020 Medtronic. All rights reserved.  
UC201809495b EN 11/2020

**Medtronic**  
Further, Together

## Melody™ Transcatheter Pulmonary Valve | Ensemble™ II Transcatheter Valve Delivery System

### Important Labeling Information for the United States

**Indications:** The Melody TPV is indicated for use in the management of pediatric and adult patients who have a clinical indication for intervention on a dysfunctional right ventricular outflow tract (RVOT) conduit or surgical bioprosthetic pulmonary valve that has  $\geq$  moderate regurgitation, and/or a mean RVOT gradient  $\geq$  35 mm Hg.

**Contraindications:** None known.

### Warnings/Precautions/Side Effects

- **DO NOT implant in the aortic or mitral position. Pre-clinical bench testing of the Melody valve suggests that valve function and durability will be extremely limited when used in these locations.**
- DO NOT use if patient's anatomy precludes introduction of the valve, if the venous anatomy cannot accommodate a 22 Fr size introducer, or if there is significant obstruction of the central veins.
- DO NOT use if there are clinical or biological signs of infection including active endocarditis. Standard medical and surgical care should be strongly considered in these circumstances.
- Assessment of the coronary artery anatomy for the risk of coronary artery compression should be performed in all patients prior to deployment of the TPV.
- To minimize the risk of conduit rupture, do not use a balloon with a diameter greater than 110% of the nominal diameter (original implant size) of the conduit for pre-dilation of the intended site of deployment, or for deployment of the TPV.
- The potential for stent fracture should be considered in all patients who undergo TPV placement. Radiographic assessment of the stent with chest radiography or fluoroscopy should be included in the routine postoperative evaluation of patients who receive a TPV.
- If a stent fracture is detected, continued monitoring of the stent should be performed in conjunction with clinically appropriate hemodynamic assessment. In patients with stent fracture and significant associated RVOT obstruction or regurgitation, reintervention should be considered in accordance with usual clinical practice.

Potential procedural complications that may result from implantation of the Melody device include the following: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, pain, swelling, or bruising at the catheterization site. Potential device-related adverse events that may occur following device implantation include the following: stent fracture,\* stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, hemolysis.

\*The term "stent fracture" refers to the fracturing of the Melody TPV. However, in subjects with multiple stents in the RVOT it is difficult to definitively attribute stent fractures to the Melody frame versus another stent.

For additional information, please refer to the Instructions for Use provided with the product or available on <http://manuals.medtronic.com>.

**CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician.

### Important Labeling Information for Geographies Outside of the United States

**Indications:** The Melody™ TPV is indicated for use in patients with the following clinical conditions:

- Patients with regurgitant prosthetic right ventricular outflow tract (RVOT) conduits or bioprostheses with a clinical indication for invasive or surgical intervention, OR
- Patients with stenotic prosthetic RVOT conduits or bioprostheses where the risk of worsening regurgitation is a relative contraindication to balloon dilatation or stenting

### Contraindications

- Venous anatomy unable to accommodate a 22 Fr size introducer sheath
- Implantation of the TPV in the left heart
- RVOT unfavorable for good stent anchorage
- Severe RVOT obstruction, which cannot be dilated by balloon
- Obstruction of the central veins
- Clinical or biological signs of infection
- Active endocarditis
- Known allergy to aspirin or heparin
- Pregnancy

**Potential Complications/Adverse Events:** Potential procedural complications that may result from implantation of the Melody device include the following: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, pain, swelling or bruising at the catheterization site. Potential device-related adverse events that may occur following device implantation include the following: stent fracture,\* stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, hemolysis.

\*The term "stent fracture" refers to the fracturing of the Melody TPV. However, in subjects with multiple stents in the RVOT it is difficult to definitively attribute stent fractures to the Melody frame versus another stent.

For additional information, please refer to the Instructions for Use provided with the product or available on <http://manuals.medtronic.com>.

The Melody Transcatheter Pulmonary Valve and Ensemble II Transcatheter Delivery System has received CE Mark approval and is available for distribution in Europe.

## medtronic.com

710 Medtronic Parkway  
Minneapolis, MN 55432-5604  
USA  
Tel: (763) 514-4000  
Fax: (763) 514-4879  
Toll-free: (800) 328-2518

**LifeLine**  
**CardioVascular Technical Support**  
Tel: (877) 526-7890  
Fax: (651) 367-0918  
[rs.structuralheart@medtronic.com](mailto:rs.structuralheart@medtronic.com)





# The PICS Society Advocacy Program: Power in Numbers! Part 1


Kamel Shibbani, MD; Natalie Poli, Ed.S; Norm Linsky, MPA, MA

Let's start a conversation about **ADVOCACY**—how our community can advocate for lasting changes to laws, regulations, R&D investment, funding, compensation and related issues that impact us all daily. Are there fundamental advocacy goals we all share? Do we, as a professional society, have the obligation to use our collective voice to affect change? Are there opportunities for doctors and patients to advocate as a team? Do we have “power in numbers” by speaking with one voice?

Based on what several of you have told us, the answers are a resounding yes, yes, yes and yes. That's the focus of this month's column and others in the coming months.

We recently posed three questions to colleagues around the world:

- What is the most pressing advocacy challenge in your country?
- What is the most important advocacy challenge globally?
- What should the PICS Society do moving forward?



Let's start the conversation by spotlighting a recent interview we had with Alejandro Peiróne, MD, FPICS, Children's Hospital of Córdoba, Argentina.

*Comments lightly edited for brevity.*

I ask myself every day how we can help improve the quality of life for patients in my country. Several vital areas come to mind.

**Economic challenges in my country:** Starting about ten years ago, my country had problems getting access to international credit and loans. This complex area affected everyone, including those of us who care for children and adults with CHD. Our country's infant mortality rate was about 14 per 1,000 newborns. This, much like our government's ability to qualify for better access to international credit, needed to improve. The government worked with us to create a national plan for improved access and quality of care for those with CHD. We worked hard with the government to implement this plan, making important progress in the past decade. Although progress is slow, we are moving in the right direction.

**Migration:** Another growing challenge relates to migration from neighboring countries. We care for all patients who come to us, but too often migrants do not have ready access to timely care, so we have much work to do—and I believe other countries face similar situations.

**Professional education:** We urgently need to improve medical education and advocate

**Sharing lessons learned:** We need to share ideas about how patients with no insurance or ability to pay can get the care they need. I believe this is a universal problem. I have participated in medical missions in Panama, Peru and elsewhere. Our team will be on site for one or two weeks. However, once we leave the overall situation stays the same. Such missions need to provide more education and involve a broader range of medical professionals. We must promote teamwork and constantly improve, educate and network. Everyone has an important role to play.

**Quality improvement:** The PICS Society can partner with national societies, doctors, hospitals and governments to develop quality improvement plans where you don't have everything. I am in Córdoba, a major city, and have extensive resources available to me. One hundred kilometers away, the situation is totally different: resources are very limited. We all need to work with our respective governments to change this through funding and training. In Argentina our government is eager to partner with us—which is very encouraging!

*“When I first came home to Argentina, I thought I could be like Superman and I could change everything quickly. In reality, change takes time. When I go home each day I feel optimistic that we are making progress! We have much work and opportunity ahead.” – Dr. Alejandro Peiróne*

for national training and quality standards. In Argentina, we have few pediatric cardiology specialists. Typically, those with CHD are treated by adult cardiologists; this is the only option. In the largest cities, the quality of prenatal diagnosis for CHD is high, but much less so in the countryside. The PICS Society can partner with national societies to develop national training standards and professional education programs—and advocate for their funding.

**Global networking:** The importance of networking, connecting and sharing ideas globally cannot be overstated. Whether we are discussing quality, education, funding, regulations or other issues, our opportunity to network to achieve common goals is what encourages me.

**Optimistic attitudes, realistic expectations:** I have been in Argentina since I completed training 20 years ago. When I first came



home to Argentina, I wanted to change everything! I thought I could be like Superman and I could change everything quickly. In reality of course, change is difficult and takes time. I go home every day and I feel optimistic to see how younger physicians and their teams are getting better training, getting published and trying hard – every day – to offer high quality health care to patients.

*Working with the national government:* If our government is to help, it needs access to data showing CHD treatment and outcomes over time: this is essential to encourage the government to continue investment in CHD care in Argentina and I am sure elsewhere. Our PICS Society has an important information sharing role in that regard.

*Final thoughts:* We very much need global cooperation. The PICS Society can partner with societies in Argentina, South America and worldwide. I am glad the Society is a global organization dedicated to international cooperation. This is a decathlon—not a hundred-meter dash!

What are your thoughts about advocacy? Want to get involved? Email [nlinsky@CHDInterventions.org](mailto:nlinsky@CHDInterventions.org). Thank you Dr. Peiróne and the PICS Society Advocacy Committee (John Cheatham, MD, Chair; Clifford Kavinsky, MD, PhD, Co-Chair; Hideshi Tomita, Co-Chair). More interviews to come next month!



**KAMEL SHABBANI, MD**

*Advanced Pediatric Cardiology Fellow*  
University of Iowa  
Iowa City, IA, USA



**NATALIE POLI, Ed.S.**

*Public Education Professional*  
Successfully treated interventional for CHD, 2006  
Senior Patient Advisor to the PICS Society  
Mrs. Illinois International 2021 1<sup>st</sup> Runner Up  
Former Captain of the NBA Chicago Bulls  
Dance Team



**NORM LINSKY, MPA, MA**

*PICS Society Executive Director*  
[nlinsky@CHDInterventions.org](mailto:nlinsky@CHDInterventions.org)




**PICS Society**

Pediatric and Congenital Interventional Cardiovascular Society



**SAVE THE DATE**  
**SEPT 1-4 2021**



Focusing on the latest interventional catheter strategies for congenital and structural heart disease in children and adults.

[www.picsymposium.com](http://www.picsymposium.com)

[www.CHDInterventions.org](http://www.CHDInterventions.org)





# Delayed Aortic Coarctation Balloon Dilatation After Duct Coil Occlusion

Francisco Javier Ozores Suárez, MD, MS; Francisco Díaz Ramirez, MD; Juan Carlos Ramiro Novoa, MD; Alejandro González Veliz, MD

**Key Words:** Patent ductus arteriosus, Coarctation of the aorta, Transcatheter treatment.

## Summary

There are different approaches to the treatment of the combination of Patent Ductus Arteriosus and Coarctation of the Aorta in children using cardiac catheterization. We report, after eight years of follow up, an unusual staged closure of Patent Ductus Arteriosus and aortic ballooning in two separate procedures with several years in between. This child underwent coil patent ductus arteriosus occlusion at nine months of age and later only aortic balloon dilatation performed at the age of six-years-old, with good outcome of the coarctoplasty and no mislay of the right positioning of the coil.

## Introduction

Small children with Coarctation of the Aorta (CoA) and Patent Ductus Arteriosus (PDA) usually undergo surgical correction, but transcatheter closure of moderate to large ductus arteriosus with occluder devices and coarctoplasty is now practiced more frequently using different techniques, devices and timing, depending on the patient.<sup>1</sup>

We report an aortic balloon dilatation and PDA closure in sequential approach, with some years in between, in a small child who first underwent coil PDA occlusion and later only aortic balloon dilatation with both balloon and coil in a very close spatial relationship.

## Clinical Case

Fifteen-year-old female adolescent with diagnosis at the age of seven months of: aortic coarctation, patency of the arterial duct, small-subaortic Ventricular Septal Defect and bicuspid aortic valve.


At the age of eight months, this patient underwent only balloon dilatation of the coarctation because, at that time, it was identified as the target lesion. Additionally, there was not consensus about the presence, or not, of an adequate diameter of the aorta to deploy a device without worsening the lumen of the aorta due to a possible bulging of the aortic retention skirt of the device, which has been reported.<sup>2,3,4</sup>

One month later the patient underwent ligation of a 4 mm PDA, but a mild to moderate residual leak was evident at the level of the PDA by echo the day after the surgery.

At the age of two years, the patient underwent transcatheter closure of the residual PDA leakage using a detachable coil with

no residual shunt. At that time there was no significant gradient at the level of the former coarctation site. However, four years later, a new coarctoplasty was indicated because after echo followup a gradient of 52 mmHg was identified at the level of the coarctation. At that time an angiotomography was also performed showing the narrowing of the aortic coarctation at the ductal level (**Figure 1**).

Before the procedure, the Telecardiogram showed a 0.59 Cardiac-Torax Index with normal pulmonary flow. The EKG showed sinus rhythm, incomplete right-bundle branch block, QRS axis 60



**FIGURE 1** Narrowing of the aortic coarctation (arrow) at the ductal ligament level.

degrees and a Sokolow index of 14 mm. The angiography prior to the interventional procedure showed a diameter of 6.8 mm at the coarctation level and the diameter of the abdominal aorta at the diaphragm level was 12mm.

Once the coarctation balloon dilatation procedure was initiated, the arch of the aorta was crossed with a 0.021 × 260 cm Terumo wire using a 6 Fr multipurpose catheter from the right femoral artery access. Conventional angioplasty was performed with a 12 X 4 mm Tyshak balloon (**Figure 2 A-C**). The ballooning was repeated twice using the hand pressure. With the procedure, the peak pressure gradient across the coarctation was reduced to 0 mmHg. During the procedure heparin was administered at 100 mg/kg. It was indicated immediately after the sheath of the femoral artery was put in place.

Post-procedure period was uneventful. Patient was discharged from the hospital five days after the intervention. At the two week follow-up, the patient was stable and remained asymptomatic. Follow-up echocardiography after eight years revealed in-situ



# INCREASE YOUR REACH

with the sizing balloon  
catheter trusted for over  
a decade.

## What Clinicians Like:



Comprehensive size offering with diameters ranging from 20mm – 40mm



Four radiopaque marker bands to enable accurate defect sizing



Low profile design for ease of deliverability and compatibility with D'VILL™ Introducer (65cm)



Braided inner lumen for optimal pushability, trackability and kink-resistance

ESTABLISHED. PROVEN. EFFECTIVE.



Now  
Available  
in 110cm  
Length

## PTS-X™ Sizing Balloon Catheter

Distributed by:

B. Braun Interventional Systems Inc. | Part of the B. Braun Group of Companies  
Bethlehem, PA | USA | 877-836-2228 | [www.bisusa.org](http://www.bisusa.org)

PDA coil device with no residual shunt and no indications of recoarctation with 15 mmHg pressure gradient at the site of coarctation balloon dilatation.

## Discussion

The transcatheter treatment for Coarctation of the Aorta associated with Patent Ductus Arteriosus in children and adults has been frequently reported in the past, performing the procedure either at the same time or sequentially.<sup>5</sup> Reports include the use of balloon, stent and even covered stent.<sup>6,7,8,9,10</sup> Due to the circumstances surrounding our patient without ample duct ampulla to have a previous sternotomy, the presence of residual shunt, and re-coarctation after surgery for PDA, we decided on re-coarctoplasty even though the patient had a previous device at the PDA site. There are previous reports in older patients with the use of Amplatzer devices at PDA level deploying a stent which included both the PDA device and the coarctation leading to better stabilization of the PDA device<sup>11</sup> but, to the best of our knowledge, this is the first report about performing a successful aortic coarctation ballooning over a detachable coil in PDA position in such a young patient with a long follow-up period.

## Conclusion


Transcatheter treatment of CoA and PDA in small children is safe. In the presence of previous PDA closure with detachable coil devices, it is possible, after some years, to perform balloon aortic dilatation with a by hand insufflation of the balloon.

**FIGURE 2**

**(A)** Aortic narrowing (red arrow) at the same level of the PDA coil occluder device (blue arrow).

**(B)** Ballooning the coarctation still showing a notch at the level of the device (arrow).

**(C)** Final angiogram showing no residual narrowing of the aorta.



## References

1. Pavlovic D., de Lezo J.S., Medina A. Sequential transcatheter treatment of combined coarctation of aorta and persistent ductus arteriosus. *Am Heart J.* 1992; 123:249–250.
2. Sun, Z., Li, D., Wang, Y. et al. Surgical removal of part of an occluder to treat iatrogenic coarctation of the aorta: a case report. *BMC Surg* 20, 17 (2020). <https://doi.org/10.1186/s12893-020-0682-6>.
3. Ottenkamp J, Hess J, Talsma MD, Buis-Liem TN. Protrusion of the device: a complication of catheter closure of patent ductus arteriosus. *Br Heart J.* 1992 Sep; 68(3):301-3. doi: 10.1136/hrt.68.9.301. PMID: 1389763; PMCID: PMC1025075.
4. Masri S, El Rassi I, Arabi M, Tabbakh A, Bitar F. Percutaneous closure of patent ductus arteriosus in children using amplatzer duct occluder II: relationship between PDA type and risk of device protrusion into the descending aorta. *Catheter Cardiovasc Interv.* 2015 Aug; 86(2):E66-72. doi: 10.1002/ccd.25940. Epub 2015 May 29. PMID: 26032159.
5. Ing F.F., McMahon W.S., Johnson G.L., Vick G.W., Mullins C.E. Single therapeutic catheterization to treat coexisting coarctation of the aorta and patent ductus arteriosus. *Am J Cardiol.* 1997; 79:535–537.
6. Sadiq M., Malick N.H., Qureshi S.A. Simultaneous treatment of native coarctation of the aorta combined with patent ductus arteriosus using a covered stent. *Catheter Cardiovasc Interv.* 2003; 59:387–390.
7. Celebi A., Yalçın Y., Erdem A., Zeybek C., Akdeniz C., Polat T.B. Successful transcatheterballoon dilatation of coarctation of aorta and coil occlusion of patent ductus arteriosus in a single catheterization procedure. *Turk J Pediatr.* 2007; 49:94–97.
8. Hekim Yılmaz E, Bulut MO, Küçük M, Yücel İK, Erdem A, Çelebi A. Use of covered stents in simultaneous management of coarctation of the aorta and patent ductus arteriosus. *Anatol J Cardiol.* 2018 Apr;19(4):332-336. doi: 10.14744/AnatolJCardiol.2018.61257. Epub 2018 Mar 21. PMID: 29578201.
9. Kulkarni S., Vimala J., Parmar R. Single therapeutic catheterization for treatment of native coarctation of aorta and large patent ductus arteriosus using a covered stent. *Indian Heart J.* 2005;57:713–716.
10. Liu PH, Kang PL, Lin YH. Young Adult Patent Ductus Arteriosus Treated with Endovascular Stent Grafting. *Acta Cardiol Sin.* 2016 Sep;32(5):619-622. doi: 10.6515/acs20151117a. PMID: 27713613; PMCID: PMC5052483.
11. Singhi AK, Sivakumar K. Different transcatheter strategies for aortic coarctation associated with patent ductus arteriosus. *Indian Heart J.* 2012 Jul; 64(4): 423–426.





**FRANCISCO JAVIER OZORES SUÁREZ, MD, MS**

Cardiologist, Assistant Professor of Pediatrics  
Pediatric Cardiac Center "William Soler"  
Havana, Cuba  
[javier.ozores@informed.sld.cu](mailto:javier.ozores@informed.sld.cu)  
053 7 8 32 89 11



**FRANCISCO DIAZ RAMIREZ, MD**

Radiologist, Assistant Professor of Pediatrics  
Pediatric Cardiac Center "William Soler"  
Havana, Cuba



**JUAN CARLOS RAMIRO NOVOA, MD**

Cardiologist, Auxiliar Professor of Pediatrics  
Pediatric Cardiac Center "William Soler"  
Havana, Cuba



**ALEJANDRO GONZÁLEZ VELIZ, MD**

Cardiologist  
Institute of Cardiology and Cardiovascular  
Surgery  
Havana, Cuba

## Publish

- Written by doctors and their team
- Case studies, articles, research findings
- Submit on your schedule
- Print and electronic
- Published within 3 months of submission
- No fees



CONGENITAL  
CARDIOLOGY  
TODAY

## SEPTEMBER

**01-04**

### PICS Society Symposium 2021

Las Vegas, NV, USA

<https://picsymposium.com/>

**23-24**

### EPIC Live – Emory Practical Intervention Course Virtual

<https://www.epicsec.org/>

## OCTOBER

**01-03**

### Echo in Congenital Heart Disease: Adult and Pediatric Cases, Including Multimodality Imaging Rochester, MN, USA

<https://cveducation.mayo.edu/store/echo-in-congenital-heart-disease-adult-and-pediatric-cases-including-multimodality-imaging>

**07-09**

### The Genetics of Heart & Vascular Disease Nashville, TN, USA

<https://cveducation.mayo.edu/store/the-genetics-of-heart-vascular-disease>

**14-16**

### Current Applications and Future of Artificial Intelligence in Cardiology

San Francisco, CA, USA

<https://cveducation.mayo.edu/store/current-applications-and-future-of-artificial-intelligence-in-cardiology>

**16**

### 11<sup>th</sup> Annual Fetal Echocardiography Symposium at UCLA: Clinical Tips and Pearls from the Experts Virtual

<https://www.cme.ucla.edu/courses/fetalecho21>





# Nationwide Children's Hospital Once Again Named on U.S. News & World Report's 2021-22 Best Children's Hospitals Honor Roll

*Eighth Consecutive Year for "Best of the Best" Recognition*

Nationwide Children's Hospital has been named once again to U.S. News & World Report's **Best Children's Hospitals** Honor Roll. The Honor Roll is a distinction awarded to only 10 children's medical centers nationwide recognized by U.S. News as the "Best of the Best." Nationwide Children's was once again recognized at number 8 on the Honor Roll list.

The 2021-22 Honor Roll designation marks the eighth consecutive year Nationwide Children's has received this distinction. The Honor Roll list is based on a hospital's cumulative ranking in 10 specialties evaluated by U.S. News.

"Despite the uncertainty posed by the COVID-19 pandemic, our team's commitment to the children in our community and globally has never wavered," said Tim Robinson, Nationwide Children's CEO. "These rankings highlight the high-quality care Nationwide Children's provides and are a testament to our incredible team."

"When choosing a hospital for a sick child, many parents want specialized expertise, convenience and caring medical professionals," said Ben Harder, chief of health analysis and managing editor at U.S. News. "The *Best Children's Hospitals* rankings have always highlighted hospitals that excel in specialized care. As the pandemic continues to affect travel, finding high-quality care close to home has never been more important."

The annual *Best Children's Hospitals* rankings, now in their 15<sup>th</sup> year, are designed to assist patients, their families and their physicians in making informed decisions about where to receive care for challenging health conditions.

The U.S. News & World Report *Best Children's Hospitals* ranking is one means of being recognized for continued progress and improvements in pursuing best outcomes, integrated care and research. For more information, visit *Best Children's Hospitals* and use #BestHospitals on Facebook and Twitter.

U.S. News & World Report's 2021-2022 *Best Children's Hospitals* rankings of Nationwide Children's individual medical specialties include:

- Cancer - #8
- Cardiology and Heart Surgery - #34
- Endocrinology - #11
- Gastroenterology and GI Surgery - #11
- Neonatology - #43
- Nephrology - #9
- Neurology and Neurosurgery - #6
- Orthopedics - #9
- Pulmonary Medicine - #7
- Urology - #11



**NATIONWIDE CHILDREN'S**  
*When your child needs a hospital, everything matters.™*

## About Nationwide Children's Hospital

Named to the Top 10 Honor Roll on U.S. News & World Report's 2020-21 list of "Best Children's Hospitals," Nationwide Children's Hospital is one of America's largest not-for-profit free-standing pediatric health care systems providing wellness, preventive, diagnostic, treatment and rehabilitative care for infants, children and adolescents, as well as adult patients with congenital disease. Nationwide Children's has a staff of more than 13,000 providing state-of-the-art pediatric care during more than 1.6 million patient visits annually. As home to the Department of Pediatrics of The Ohio State University College of Medicine, Nationwide Children's physicians train the next generation of pediatricians and pediatric specialists. The Abigail Wexner Research Institute at Nationwide Children's Hospital is one of the Top 10 National Institutes of Health-funded free-standing pediatric research facilities.

More information is available at [www.NationWideChildrens.org](http://www.NationWideChildrens.org).



**NEONATOLOGY TODAY**  
Peer Reviewed Research, News and Information in Neonatal and Perinatal Medicine

Neonatology Today is interested in publishing manuscripts from Neonatologists, Fellows, NNPs and those involved in caring for neonates on case studies, research results, hospital news, meeting announcements, and other pertinent topics.

Please submit your manuscript to: [LomaLindaPublishingCompany@gmail.com](mailto:LomaLindaPublishingCompany@gmail.com)



# Phoenix Children's Ranked in all 10 Specialties by U.S. News & World Report's Best Children's Hospitals

*The Health System is Arizona's Only Children's Hospital Ever to be Named to the List*

For the fifth time, **Phoenix Children's Hospital** has earned national rankings from *U.S. News & World Report's Best Children's Hospitals* in 10 out of 10 ranked specialties. The health system is the only children's hospital in Arizona ever to have been recognized by *U.S. News & World Report* and one of only 22 children's hospitals in the United States to rank in **every surveyed specialty** for 2021-2022.



"We are incredibly proud of our clinicians, administrators and staff who overcame immense challenges last year and redoubled their efforts to provide hope and healing to Arizona families," said Robert L. Meyer, President and CEO of Phoenix Children's. "We've set our sights on becoming the top destination for pediatric health care in the region. Key to this goal is our ever-expanding footprint as Phoenix Children's brings high-quality services closer to home for families in the West Valley, the East Valley and throughout Arizona."

Every year, *U.S. News & World Report* ranks children's hospitals in 10 clinical specialties using a variety of measures including clinical

expertise, patient outcomes and national reputation. The 2021-22 rankings mark the 11<sup>th</sup> consecutive year Phoenix Children's has been named among the nation's "**Best Children's Hospitals**" and the fifth time the health system has received high marks in all 10 areas:

- Neonatology - #20
- Cardiology & Heart Surgery - #28, represented by Phoenix Children's Heart Center
- Neurology & Neurosurgery - #30, represented by Barrow Neurological Institute at Phoenix Children's
- Orthopedics - #33, represented by the Herbert J. Louis Center for Pediatric Orthopedics and Sports Medicine
- Nephrology - #35
- Cancer - #36, represented by Phoenix Children's Center for Cancer and Blood Disorders
- Gastroenterology & Gastroenterology Surgery - #36
- Diabetes & Endocrinology - #37
- Pulmonology & Lung Surgery - #40
- Urology - #48

"Achieving top rankings in all 10 specialties reflects the strength of our reputation for clinical excellence among

physicians nationwide and as a pediatric health system offering world-class care," said Michael Ritchey, MD, Senior Vice President and Chief Medical Officer at Phoenix Children's. "This recognition validates our hard work over the past year, but we are not content to rest on our laurels and will continue to push for the best clinical outcomes for our patient families."

Scoring for *Best Children's Hospitals* includes objective measures such as patient outcomes as well as a hospital's available clinical resources and compliance with best practices. Rankings also reflect survey results from thousands of pediatric specialists who rate children's health systems based on where they would send their sickest patients, without respect to proximity or cost.

Phoenix Children's *Best Children's Hospital* recognition is one of many clinical distinctions the health system achieved recently. In the past year, Phoenix Children's was verified a Level 1 Children's Surgery Center from the American College of Surgeons, earned accreditation from the Adult Congenital Heart Association as an Adult Congenital Heart Disease Comprehensive Care Center, was verified a Tourette Association of America Center



of Excellence in partnership with Banner Sun Health Research Center, and was named Hospital of the Month by Children's Hospitals' Solutions for Patient Safety.

## About Phoenix Children's

Phoenix Children's is one of the nation's largest pediatric health systems. It comprises: Phoenix Children's Hospital—Main Campus, Phoenix Children's Hospital—East Valley at Dignity Health Mercy Gilbert Medical Center, four pediatric specialty and urgent care centers, 11 community pediatric practices, 20 outpatient clinics, two ambulatory surgery centers and six community-service-related outpatient clinics throughout the state of Arizona. The system has provided world-class inpatient, outpatient, trauma, emergency and urgent care to children and families for more than 35 years. Phoenix Children's Care Network includes more than 850 pediatric primary care providers and specialists who deliver care across more than 75 subspecialties. For more information, visit us at

<http://phoenixchildrens.org/>.



# CHiP NETWORK

CONGENITAL HEART INTERNATIONAL PROFESSIONALS



## CORPORATE TEAM

**FOUNDER &  
SENIOR EDITOR**

Tony Carlson  
*tcarlsonmd@gmail.com*

**CO-FOUNDER &  
MEDICAL EDITOR**

John W. Moore, MD, MPH  
*jwmmoore1950@gmail.com*

**PUBLISHER &  
EDITOR-IN-CHIEF**

Kate Baldwin  
*kate.f.baldwin@gmail.com*

**STAFF EDITOR &  
WRITER**

Virginia Dematatis

**EDITOR-IN-CHIEF  
EMERITUS**

Richard Koulbanis

**STAFF EDITOR**

Loraine Watts

## EDITORIAL BOARD

Teiji Akagi, MD  
Zohair Al Halees, MD  
Mazeni Alwi, MD  
Felix Berger, MD  
Fadi Bitar, MD  
Jacek Bialkowski, MD  
Mario Carminati, MD  
Anthony C. Chang, MD, MBA  
John P. Cheatham, MD  
Bharat Dalvi, MD, MBBS, DM  
Horacio Faella, MD  
Yun-Ching Fu, MD

Felipe Heusser, MD  
Ziyad M. Hijazi, MD, MPH  
Ralf Holzer, MD  
Marshall Jacobs, MD  
R. Krishna Kumar, MD, DM, MBBS  
John Lamberti, MD  
Gerald Ross Marx, MD  
Tarek S. Momenah, MBBS, DCH  
Toshio Nakanishi, MD, PhD  
Carlos A. C. Pedra, MD  
Daniel Penny, MD, PhD  
James C. Perry, MD

Shakeel A. Qureshi, MD  
P. Syamasundar Rao, MD  
Andrew Redington, MD  
Carlos E. Ruiz, MD, PhD  
Girish S. Shirali, MD  
Horst Sievert, MD  
Hideshi Tomita, MD  
Gil Wernovsky, MD  
Zhuoming Xu, MD, PhD  
William C. L. Yip, MD  
Carlos Zabal, MD

## OFFICIAL NEWS & INFORMATION PARTNER OF



**PICS Society**

Pediatric and Congenital Interventional Cardiovascular Society